Leadership Team



Appointed July 2018, having previously served as executive chairman and non-executive director.

Previously at IP Group Plc, leading the Healthcare team, and pre-clinical drug discovery CRO, Exelgen (previously Tripos Discovery Research)

PhD, MSc, BSc (Hons) Chemistry. Chartered Chemist and member of the Royal Society of Chemistry.



Previously COO at Power Networks Demonstration Centre and Director of Software Engineering at GE Digital Energy.

Director and Founder of computer software business 3Ideas.


Chief Business Officer

Appointed June 2021.

Over 25 years’ experience in the life sciences technology sector spanning company formation, business development and investment. Previous investor roles at Bioscience Managers PTY and IP Group PLC and business development roles at Abcodia and Quotient Sciences, a clinical drug development CRO.

PhD, Molecular Virology; BSc (Hons) First Class Microbiology and Biotechnology and MBA with distinction.


Chief Financial Officer

Fraser has 17 years of accounting experience and significant exposure to fast-growing software businesses having worked at Tradeweb Inc., a NASDAQ listed electronic fixed income and derivatives trading platform, for eight years, latterly as Finance Director, Europe and Asia, supporting the Group's international growth.


Chief of Staff

Joined the management team as Chief of Staff in early 2021 having being our Executive Assistant since June 2019. Jenny previously held positions at IP Group Plc and Reed Specialist Recruitment managing all aspects of business administration in SME’s.

Glyn Williams

Chief Product Officer

With over 25 years’ experience in life science technology, Glyn was a key member of the IDBS leadership team with extensive experience of global sales, marketing, product management, product development and customer support. 


Synthetic Chemist

An experienced synthetic chemist, with a track record of delivering complex projects within the pharma and biotech sectors. David built and ran a business focused on automated medicinal chemistry, where compounds would be synthesised, then tested in a primary assay on the same platforms, with the results fed back into the software to inform the next round of automated synthesis.